Introducing Valuation Models! 
Earnings growth is one of the most powerful drivers of long-term stock returns.
When a company consistently increases earnings, it often leads to stronger investor demand, higher valuations, and ultimately, higher share prices.
Here are 10 stocks analysts expect to deliver explosive earnings growth in the years ahead.
Find high-quality high-growth stocks with TIKR today (It’s free) >>>
Here are a few of our favorite stocks from this list:
DraftKings (DKNG)
- Market Cap: $18 billion
- Industry: Leisure
- Analyst Upside: 42%
- P/E Ratio: 24
Company Overview: DraftKings Inc. (DKNG) is a digital sports entertainment and gaming company that offers online sports betting, iGaming, and daily fantasy sports across the U.S. and internationally. The platform combines technology, data, and immersive design to create a personalized and competitive betting experience.
Business Strategy: DraftKings generates revenue through sports betting handle, online casino gaming, and fantasy sports entry fees. Its strategy centers on expanding into newly legalized states, growing user engagement, and increasing profitability through improved customer retention and operational efficiency.
Recent Developments:
- Earnings & Profitability: In Q1 2025, DraftKings beat revenue and earnings expectations, and EBITDA turned positive due to strong customer acquisition, higher hold rates, and disciplined marketing spending.
- Business Growth Trends: DraftKings continues to grow its footprint by launching in new markets and rolling out product enhancements like in-game micro-betting and parlay customization to deepen user engagement.
- Shareholder Returns: Although DraftKings does not offer a dividend, the company is focused on reaching sustained profitability and improving free cash flow, which could pave the way for future capital return strategies.
Analyze stocks like DraftKings quicker with TIKR >>>
Udemy, Inc. (UDMY)
- Market Cap: $1 billion
- Industry: Diversified Consumer Services
- Analyst Upside: 32%
- P/E Ratio: 16.1
Company Overview: Udemy, Inc. (UDMY) is a global online learning platform that connects instructors with learners seeking to gain professional skills. The company operates through two main segments: Udemy Business, which serves organizations, and its direct-to-consumer marketplace.
Business Strategy: Udemy makes money by selling individual courses and enterprise learning subscriptions. Udemy’s strategy focuses on expanding its B2B segment, scaling international markets, and improving platform engagement to drive long-term growth.
Recent Developments:
- Earnings & Profitability: Udemy has narrowed losses and improved margins, supported by cost controls and growing subscription revenue from Udemy Business.
- Business Growth Trends: Enterprise demand is rising, with Udemy Business now a key growth driver as organizations invest more in workforce upskilling.
- Shareholder Returns: While not yet profitable, Udemy has a solid cash position and is focusing on sustainable growth rather than near-term returns.
Track Udemy’s financials, growth trends, and analyst forecasts on TIKR >>>
Eli Lilly and Company (LLY)
- Market Cap: $162 billion
- Industry: Pharmaceuticals
- Analyst Upside: 20%
- P/E Ratio: 33.2
Company Overview: Eli Lilly and Company (LLY) is a global pharmaceutical leader headquartered in Indianapolis, Indiana. The company specializes in innovative treatments across diabetes, oncology, immunology, and neuroscience, with key brands including Mounjaro, Zepbound, and Jardiance.
Business Strategy: Lilly generates revenue through a diversified portfolio of patented medicines, focusing on high-growth areas like obesity, diabetes, and cancer. The company aims to accelerate growth by expanding its pipeline, enhancing manufacturing capabilities, and pursuing strategic acquisitions.
Recent Developments:
- Earnings & Profitability: In Q1 2025, Eli Lilly grew revenue 45% year-over-year to $12.73 billion, with strong sales from Mounjaro and Zepbound, while adjusted EPS rose 29% to $3.34.
- Business Growth Trends: Lilly reaffirmed its 2025 revenue outlook of $58–$61 billion, fueled by global demand for its diabetes and obesity treatments and promising pipeline advancements.
- Shareholder Returns: In late 2024, Lilly approved a $15 billion share repurchase program and raised its dividend by 15%, continuing its multi-year focus on returning capital to shareholders.
Find stocks that we like even better than Eli Lilly today with TIKR (It’s free) >>>
TIKR Takeaway
With rates still elevated and investors watching for signs of an economic slowdown, earnings growth is more important than ever.
The stocks on this list stand out for their strong earnings momentum in a tricky market.
- Looking for stocks with long-term growth potential? Browse TIKR’s stock screener to find the best stocks to buy today.
- Already love the stocks you own? Get real-time news and in-depth stock insights when you add your holdings to your watchlist on TIKR.
- Want to stay ahead? TIKR’s analysts’ estimates give you 5 years of Wall Street forecasts so you can feel confident in the stocks you invest in.
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
